Baker Bros. Advisors’s Viking Therapeutics VKTX Stock Holding History

Baker Bros. Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-366,083	Closed	-$9.62M	–	97
2025 Q3	$9.62M	Buy	+366,083	New	+$10.9M	0.07%	64
2021 Q2	–	Sell	-363,980	Closed	-$2.3M	–	128
2021 Q1	$2.3M	Hold	363,980	–	–	0.01%	113
2020 Q4	$2.05M	Sell	363,980 -40,220	-10%	-$244K	0.01%	110
2020 Q3	$2.35M	Sell	404,200 -20,800	-5%	-$143K	0.01%	100
2020 Q2	$3.06M	Hold	425,000	–	–	0.01%	87
2020 Q1	$1.99M	Hold	425,000	–	–	0.01%	90
2019 Q4	$3.41M	Hold	425,000	–	–	0.02%	79
2019 Q3	$2.92M	Hold	425,000	–	–	0.02%	77
2019 Q2	$3.53M	Hold	425,000	–	–	0.02%	69
2019 Q1	$4.22M	Hold	425,000	–	–	0.03%	63
2018 Q4	$3.25M	Hold	425,000	–	–	0.03%	63
2018 Q3	$7.4M	Buy	+425,000	New	+$5.06M	0.05%	59

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Baker Bros. Advisors's VKTX Position: Q4 2025 in Review

Baker Bros. Advisors sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 366,083 shares — an estimated $9.62M sold.

Baker Bros. Advisors first reported a position in VKTX in Q3 2018 and held it in 12 quarters. The position peaked at $9.62M in Q3 2025. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Baker Bros. Advisors reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Baker Bros. Advisors sold 366,083 Viking Therapeutics shares in Q4 2025, an estimated $9.62M.
Baker Bros. Advisors first reported a position in Viking Therapeutics in Q3 2018 and held it in 12 quarters.
Baker Bros. Advisors's Viking Therapeutics position peaked at $9.62M in Q3 2025.
426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Baker Bros. Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.